Drug Profile

Deuterated1 S-lenalidomide - Celgene Corporation

Alternative Names: D1-S-lenalidomide; Deuterated1-S-lenalidomide; DP-053

Latest Information Update: 28 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Deuteria Pharmaceuticals
Developer Celgene Corporation
Class Antineoplastics; Organic deuterium compounds
Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cell proliferation inhibitors; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors; Vascular endothelial growth factors inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Apr 2026 No recent reports of development identified for preclinical development in Cancer in USA
05 Aug 2024 Deuteria Pharmaceuticals has patent protection for a deuterated S-lenalidomide in the US
31 Dec 2012 Preclinical trials in Cancer in USA (unspecified route) before December 2012 (DeuteRx website, August 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com